New FDA Guidance on Endpoints for Demonstrating Effectiveness of Drugs for Treatment of Opioid Use Disorder

Use and abuse of opioid products has increased alarmingly over the last 20 years. Read our article discussing the latest FDA guidance on the development of new drug treatments for opioid use disorder.

Authors:

Christine Moore, PhD

Vice President, Neuroscience, Scientific Solutions

Henry J. Riordan, PhD

Chief Development Officer